Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 6 | Respiratory Research

Fig. 6

From: STAT6 deficiency mitigates the severity of pulmonary arterial hypertension caused by chronic intermittent hypoxia by suppressing Th2-inducing cytokines

Fig. 6

IL-4 promotes the proliferation of hPASMCs. The concentration of IL-4 (A) and IL-13 (B) in serum from STAT6-/- and WT mice after 6 weeks of normoxia or CIH exposure (n = 6 per group). The concentration of IL-4 (C) and IL-13 (D) in BALF from STAT6-/- and WT mice after 6 weeks of normoxia or CIH exposure (n = 6 per group). (E) CCK8 analysis of hPASMCs with IL-4 treatment under concentration of 0, 0.5, 1,10, and 100 ng/ml. (F) CCK8 analysis of hPASMCs with IL-13 treatment under concentration of 0, 0.5, 1,10, and 100 ng/ml. (G) The percentage of Ki67-positive cells in 10ng/ml IL-13 or IL-4 treated hPASMCs. Data are presented as the mean ± SD. No significant difference is indicated by ns. Significant differences are presented as *(p < 0.05), **(p < 0.01), ***(p < 0.001) and determined by Student’s t-test unless specified. hPASMCs: human pulmonary artery smooth muscle cells; Nor: normoxic; CIH: chronic intermittent hypoxia; WT: wide type; BALF: bronchoalveolar lavage fluid

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us